HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Current Status of Endoluminal Treatment of Descending Thoracic Aortic Aneurysms.

Abstract
Thoracic endovascular aortic repair (TEVAR) was proved to be effective in thoracic descending aortic aneurysm (TDAA) repair in 1994 and approved by the FDA in 2005. Since then, TEVAR has become the first-line, recommended treatment for intact or ruptured DTAA or as a bridge to definitive open surgical repair in connective tissue disease. TEVAR has decreased perioperative morbidity and mortality compared to open surgery due to the lack of thoracotomy, aortic cross-clamping and left heart bypass. Improvement in materials, manufacturing and device delivery systems have allowed for the expansion of indications. Thoughtful and accurate pre-procedure planning is the hallmark of successful TEVAR. Familiarization and adherence to the instructions for use for an aortic device will give the best possible chance of success.
AuthorsA Claire Watkins, Alex Dalal, Jason T Lee, Michael D Dake
JournalCardiovascular and interventional radiology (Cardiovasc Intervent Radiol) Vol. 43 Issue 12 Pg. 1770-1778 (Dec 2020) ISSN: 1432-086X [Electronic] United States
PMID32449019 (Publication Type: Journal Article, Review)
Topics
  • Aortic Aneurysm, Thoracic (surgery)
  • Blood Vessel Prosthesis Implantation (methods)
  • Endovascular Procedures (methods)
  • Humans
  • Reoperation
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: